Menu
Search
Home > Courses > ACTHIV 2016 Conference - The Door is Open PrEP in Practice

ACTHIV 2016 Conference - The Door is Open PrEP in Practice

ACTHIV 2016 Conference - The Door is Open PrEP in Practice
Play
Sorry, this learning module is not available for mobile devices.
ACTHIV
Original Release Date: 4/29/2016
Review Date: 9/15/2016
Presenter
  • Antonio E. Urbina, MD
    Associate Professor of Medicine, Medical Director
    Mt. Sinai Institute for Advanced Medicine
Presenter Bio
Antonio Urbina, MD

Antonio E. Urbina, MD is the Medical Director for the Mt. Sinai Institute for Advanced Medicine Downtown clinic in New York City. Dr. Urbina serves as a Medical Director for the Clinical Education Initiative of the New York State Department of Health AIDS Instituteas well as Associate Professor of Medicine at the Icahn School of School of Medicine at Mount Sinai. Since completing his residency in Internal Medicine at Saint Vincent Catholic Medical Center-Manhattan in 1995, Dr. Urbina has pioneered innovative educational programming for community-based clinics, hospitals, and public health departments. He has directed more than 10 HIV clinical trials research protocols. From 2007 to 2009, Dr. Urbina served on the Presidential Advisory Council on HIV/AIDS (PACHA) as well as Governor Cuomo’s Task Force to end the AIDS epidemic in New York State.

Continuing Education Credit (The CE accreditation for this course has expired - this section is only for your information)
The enduring material is jointly provided by William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 10th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 28-30, 2016 in Dallas, TX. The Conference was supported by funding from the Clinical Education Initiative, New York State Department of Health, AIDS Institute; and from the HIV Medicine Association (HIVMA). The conference and this web archive were supported by educational grants from Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare.

Bibliographic Sources: